ArticlePolymers2026
A Biomimetic NAC-Loaded PCL/Modified Chitosan/dECM Fibrous Scaffold for Accelerating Diabetic Wound Healing and Minimizing Scarring.
Article in Polymers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The development of innovative wound dressings capable of accelerating diabetic wound healing while simultaneously reducing scar formation is a significant clinical challenge. In this study, we designed and fabricated a multifunctional nanofibrous scaffold PCL/Az-CS/dECM/NAC by incorporating decellularized extracellular matrix (dECM) and N-acetylcysteine (NAC) into a composite backbone of polycaprolactone (PCL) and azidobenzoic acid-modified chitosan (AZCS). The scaffold exhibited ideal hydrophilicity and swelling capacity, and demonstrated excellent biocompatibility. In vitro studies demonstrated that the scaffold effectively scavenged reactive oxygen species (ROS) and promoted the polarization of macrophages from the M1 phenotype to the M2 phenotype; in vivo studies confirmed that the PCL/AZ-CS/dECM/NAC scaffold significantly accelerated wound closure, promoted mature angiogenesis, and facilitated orderly collagen deposition. The PCL/AZ-CS/dECM/NAC scaffold mitigated scar formation by increasing the proportion of regenerative type III collagen, optimizing the collagen I/III ratio. Our findings suggest that the PCL/AZ-CS/dECM/NAC scaffold is a highly promising candidate for a multifunctional dressing designed to treat recalcitrant diabetic wounds and prevent excessive scarring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.